Pfizer/BioNTech COVID-19 Vaccine Will Miss US Election, Bourla Clarifies
Pfizer CEO says that an EUA request for its COVID-19 vaccine is unlikely before late November. Analyst calls Pfizer’s development pace an encouraging sign it could be a more nimble company.
You may also be interested in...
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.
Alnylam shows that lumasiran offers similar safety and efficacy in primary hyperoxaluria type 1 patients who are six or younger as it does in older patients. US and EU regulatory decisions loom.
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.